EANS-News: MIV Therapeutics Inc.
MIV THERAPEUTICS UPDATE ON CONTRACTS
03.05.2012 – 12:17
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Contracts Richmond BC (euro adhoc) - April 30, 2012, Vancouver, British Columbia (OTC Pinks: MIVI) MIV Therapeutics, Inc. (the "Company" or "MIV") announced that MIV finalize the arrangement of payment with Purple Medical Solution of India for the sale of MIV India division, in which accordingly to the fifth amended Sale and Purchase Agreement between the two parties, Purple Medial Solution will settle the outstanding balance by monthly payment before Oct 2012, with immediate effect. Furthermore,the two parties will continue to endeavor to a new structure in order to inject an operating stent manufacturer with significant revenue and profit as major shareholder of current MIV Therapeutics, and MIV will develop further market expansion as well as CE marking accreditation for the best interest of all shareholders. MIV has also engaged one of the leading IR companies Euro Ad Hoc as its agent in Europe to facilitate the investors relationship as part of MIV's further marketing and branding process as part of the strategic plan. About MIV Therapeutics, Inc. MIV Therapeutics, Inc. is a development stage company in the business of developing next-generation coatings and drug-delivery systems for cardiovascular stents and other implantable medical devices. Safe Harbour Statements Except for the statements of historical fact contained herein, the information presented in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans, "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and should be viewed as "forward-looking statements". Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports filed with the United States Securities and Exchange Commission (the "SEC") (available at www.sec.gov) and with Canadian securities administrators (available at www.sedar.com). Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the SEC. The Company again cautions investors that the Company is not up-to-date in its SEC or SEDAR filings. Pink OTC Markets has discontinued the display of quotes on otcmarkets.com for the Company's securities because the Company's securities have been labeled Caveat Emptor (Buyer Beware) and because adequate current information has not been made available by the Company. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the Company nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Contacts: MIV Therapeutics, Inc. Fax: +1 604 357 1640 Further inquiry note: Fax: +1 604 357 1640 end of announcement euro adhoc -------------------------------------------------------------------------------- company: MIV Therapeutics Inc. Viking Way #250-4320 CA-V6V2L4 Richmond BC FAX: +1 604 357 1640 sector: Pharmaceuticals ISIN: US55306V2051 indexes: stockmarkets: free trade: Stuttgart language: English